All In Biotech

Drug Trial Radar · NCT07932639

Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis

The Secondary Preventive Effect of Long-term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Cerebral Infarction Patients With Symptomatic Moderate to Severe Intracranial Arterial Stenosis: A Single-Center, Randomized, Open-Label, Blinded-Endpoint Clinical Trial (SPDACSIS-RCT)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Mar 21, 2026

Primary completion

Feb 28, 2029

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Second Affiliated Hospital of Soochow UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate whether long-term dual antiplatelet therapy (DAPT) with cilostazol reduces the risk of recurrent symptomatic ischemic stroke or all-cause mortality compared with single antiplatelet therapy (SAPT) in patients with symptomatic moderate-to-severe intracranial arterial stenosis, following the completion of standard DAPT.

Conditions

  • Ischemic Stroke
  • Symptomatic Intracranial Atherosclerotic Stenosis

Interventions

  • CilostazolDrug

    Cilostazol 50 mg twice daily for 12 months. Cilostazol is administered in the experimental arm in combination with one antiplatelet agent: aspirin, clopidogrel, or ticagrelor.

  • AspirinDrug

    Aspirin 100 mg once daily for 12 months. Aspirin may be administered in combination with cilostazol in the experimental arm or as single antiplatelet therapy in the active comparator arm.

  • ClopidogrelDrug

    Clopidogrel 75 mg once daily for 12 months. Clopidogrel may be administered in combination with cilostazol in the experimental arm or as single antiplatelet therapy in the active comparator arm.

  • TicagrelorDrug

    Ticagrelor 90 mg twice daily for 12 months. Ticagrelor may be administered in combination with cilostazol in the experimental arm or as single antiplatelet therapy in the active comparator arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Recurrent Symptomatic Ischemic Stroke or All-Cause DeathTime frame: From randomization through 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.